Memantine: Update on the current evidence

International Journal of Geriatric Psychiatry

Volumn 18, Issue SUPPL. 1, 2003, Pages

  Möbius, Hans J ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Alzheimer's disease; Memantine; Randomized controlled trial; Vascular dementia

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; GLUTAMATE RECEPTOR AGONIST; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; TAU PROTEIN;

AGITATION; ALZHEIMER DISEASE; AUTOMUTILATION; CARDIOVASCULAR DISEASE; CAREGIVER; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CONSTIPATION; COUGHING; DATA BASE; DEGENERATIVE DISEASE; DIARRHEA; DOSE CALCULATION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MAINTENANCE DRUG DOSE; MULTIINFARCT DEMENTIA; NONHUMAN; PHARMACODYNAMICS; PROTEIN PHOSPHORYLATION; SIDE EFFECT; URINE INCONTINENCE; VERTIGO;

DEMENTIA; EVIDENCE-BASED MEDICINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 0141483720     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.939     Document Type: Conference Paper

References (36)

1. Barnes CA, Danysz W, Parsons CG. 1996. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8: 565-571.
2. Cacabelos R, Takeda M, Winblad B. 1999. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 14(1): 3-47.
3. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G. 2000. Neuroprotection and symptomatological action of memantine relevant for Alzheimer's Disease - An unified hypothesis on the mechanism of action. Neurotox Res 2(2-3): 85-98.
4. Davies P. 1999. Challenging the cholinergic hypothesis in Alzheimer disease [editorial]. JAMA 281(15): 1433-1444.
5. Ditzler K. 1991. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41: 773-780.
6. Farlow MR, Tariot PN, Grossberg GT, et al. 2003. Memantine/donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease. Neurology 60(S1): A412.
7. Fratiglioni L, De Ronchi D, Agüero-Torres H. 1999. Worldwide prevalence and incidence of dementia. Drug & Ageing 15: 365-375.
8. Galasko D, Bennett D, Sano M, et al. 1997. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimers Dis Assoc Disord 11(Suppl. 2): 33-39.
9. Galasko DR, Schmitt FA, Jin S, et al. 2000. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging 21(1S): 168.
10. Görtelmeyer R, Erbler H. 1992. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneim Forsch Drug Res 42(7): 904-913.
11. Greenamyre J, Young A. 1989. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10: 593-602.
12. Hartmann S, Möbius HJ. 2003. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. International Clinical Psychopharmacology 18(2): 81-85.
13. Jorm AF, Jolley D. 1998. The incidence of dementia: A meta-analysis. Neurology 51(3): 725-733.
14. Kornhuber J, Weller M. 1997. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy. Biol Psychiatry 41(2): 135-144.
15. Lancelot E, Beal MF. 1998. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 116: 331-347.
16. Launer LJ, Hofman A. 2000. Frequency and impact of neurologic diseases in the elderly of Europe: A collaborative study of population-based cohorts. Neurology 54(11 Suppl. 5): 1-8.
17. Lobo A, Launer LJ, Fratiglioni L, et al. 2000. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl. 5): S4-S9.
18. Möbius HJ, Stöffler A. 2003. Memantine in vascular dementia. Int Psychogeriatr 15(S1): 207-213.
19. Möbius HJ. 1999. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Disease and Associated Disorders 13(3): 172-178.
20. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. 2002. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized placebo-controlled trial (MMM 300). Stroke 33(7): 1834-1839.
21. Palmer AM, Gershon S. 1990. Is the neuronal basis of Alzheimer's disease cholinergic or glutamergic? FASEB J 4: 2745-2752.
22. Parsons CG, Danysz W, Quack G. 1998. Glutamate in CNS disorders as a target for drug development: An update. Drug News Perspect 11(9): 523-569.
23. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. 1993. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32(12): 1337-1350.
24. Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, et al. 2000. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 54: 1965-1971.
25. Reisberg B, Doody R, Stöffler A, et al. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348(14): 1333-1341.
26. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. 1980. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7(5): 486-488.
27. Saxton J, McGonigle KL, Swihart AA, Boller F. 1993. The Severe Impairment Battery. The University of Pittsburgh of the Commonwealth System of Higher Education (eds). Thames Valley Test Company: Suffolk; 1-16.
28. Sclan SG, Reisberg B. 1992. Functional assessment staging (FAST) in Alzheimer's disease: Reliability, validity, and ordinality. Int Psychoger 4(Suppl. 1): 55-69.
29. Szatkowski M, Atwell D. 1994. Triggering and execution of neuronal death in brain ischaemia: Two phases of glutamate release by different mechanisms. Trends Neurosci 17(9): 359-365.
30. Van Der Kam P, Mol F, Wimmers MFHC. 1986. [Assessment Scale for Geriatric Patients] Beordelingsschaal voor Oudere Patienten (BOP). Van Loghum Slaterus: The Netherlands.
31. Wilcock G, Möbius HJ, Stöffler A. 2002. A double-blind, placebo-controlled multicenter study of memantine in mild to moderate vascular dementia (MMM 500). International Clinical Psychopharmacology 17(6): 297-305.
32. Wimo A, Wetterholm AL, Mastey V, Winblad B. 1998. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In Health Economics of Dementia, Wimo A, Jönsson B, Karlsson G, Winblad B (eds). John Wiley: Chichester, UK; 465-499.
33. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. 2003. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. PharmacoEconomics 21(5): 327-340.
34. Winblad B, Poritis N. 1999. Memantine in severe dementia, results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psych 14(2): 135-146.
35. Winblad B, Wimo A, Möbius HJ, Fox JM, Fratiglioni L. 1999. Severe dementia: A common condition entailing high costs at individual and societal levels. Int J Geriatr Psychiatry 14(11): 911-914.
36. Zajaczkowski W, Quack G, Danysz W. 1996. Infusion of (+)-MK-801 and memantine - Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296: 239-246.